AJANTPHARM:NSE-Ajanta Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSE

Last Closing Price

INR 1,238.55

Change

+62.00 (+5.27)%

Market Cap

INR 108.14B

Volume

0.36M

Average Target Price

INR 1,545.00 (+24.74%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ajanta Pharma Limited, a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers products in various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory, general and health products, dermatology, ophthalmology, pain management, and others. The company provides its products in various dosage forms, including multivitamins, antibiotics, eye drops, cough syrups, etc. The company sells the branded generics in Asia, Africa, the Middle East, and the Commonwealth of Independent States; and the generics in the United States. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DIVISLAB:NSE Divi's Laboratories Limited

-20.75 (-1.10%)

INR512.93B 40.06 27.77
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-32.05 (-1.09%)

INR454.36B 28.12 10.69
LUPIN:NSE Lupin Limited

-10.55 (-1.89%)

INR298.53B 102.46 11.45
CADILAHC:NSE Cadila Healthcare Limited

-4.15 (-1.62%)

INR277.54B 22.28 11.88
ALKEM:NSE Alkem Laboratories Limited

+37.85 (+1.64%)

INR274.18B 24.80 19.74
AUROPHARMA:NSE Aurobindo Pharma Limited

+30.85 (+8.54%)

INR194.77B 7.59 5.18
IPCALAB:NSE Ipca Laboratories Limited

-44.75 (-3.47%)

INR160.32B 25.82 17.52
APLLTD:NSE Alembic Pharmaceuticals Limite..

+1.00 (+0.19%)

INR100.92B 13.77 11.17
NATCOPHARM:NSE NATCO Pharma Limited

+19.30 (+4.05%)

INR90.80B 18.69 13.17
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-9.05 (-4.35%)

INR58.64B 8.17 4.85

ETFs Containing AJANTPHARM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 26.58% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.58% 98% A+ 99% A+
Trailing 12 Months  
Capital Gain 20.79% 90% A- 97% A+
Dividend Return 1.27% 90% A- 64% D
Total Return 22.05% 90% A- 97% A+
Trailing 5 Years  
Capital Gain 2.80% 56% F 71% C-
Dividend Return 4.07% 57% F 38% F
Total Return 6.86% 56% F 70% C-
Average Annual (5 Year Horizon)  
Capital Gain -4.30% 34% F 34% F
Dividend Return 0.66% 60% D- 45% F
Total Return -3.64% 34% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 24.22% 71% C- 80% B-
Risk Adjusted Return -15.03% 34% F 32% F
Market Capitalization 108.14B 86% B 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.38 27% F 18% F
Price/Book Ratio 4.38 19% F 9% F
Price / Cash Flow Ratio 28.85 18% F 9% F
EV/EBITDA 15.60 22% F 17% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 17.12% 82% B- 80% B-
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 0.03% 88% B+ 89% B+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.06 80% B- 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector